Michelle Obama has left a very important legacy in the United States, especially in the health sector with medical care and ...
Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...
Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...
The FDA says new labels will make it easier to spot harmful ingredients. A UVA nutritionist suggests taking a holistic ...
Stacker on MSN3d
Diabetes and other chronic conditions are becoming common. Here's how public health efforts can help bring rates down.Dialysis Centers used data from the Centers for Disease Control and Prevention to examine the prevalence of chronic diseases ...
Intense backlash prompted the reinstatement of some online resources. But guidelines for safe contraception and information ...
Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast. Sales of ...
Today, the American Diabetes Association® (ADA) announced a new suite of resources to support improved care for those living with obesity. The resources are part of a nationwide collaboration between ...
Rep. Chip Roy (R-TX) issued a diagnosis for America’s broken health care system, and the congressman says the problem isn’t what people think.
Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.
The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback